Perez-Alcantara, Marta
Honoré, Christian
Wesolowska-Andersen, Agata
Gloyn, Anna L.
McCarthy, Mark I.
Hansson, Mattias
Beer, Nicola L.
van de Bunt, Martijn
Funding for this research was provided by:
Russell Berrie Foundation
European Union’s Seventh Framework Programme (FP7/2007-2013)
Medical Research Council (MR/L020149/1)
National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme
Innovative Medicines Initiative (115439)
Novo Nordisk
Wellcome Trust (H5R00430)
Article History
Received: 12 January 2018
Accepted: 12 March 2018
First Online: 19 April 2018
Duality of interest
: MH and CH are employees of, and shareholders in, Novo Nordisk. The remaining authors declare that there is no duality of interest associated with this manuscript.